EpiCast Report: Crohn’s Disease - Epidemiology Forecast to 2026

Invite Credit Card Holder to pay

Requester Details

Credit Card Holder Details

Company Details

Message to be included

Crohn’s disease (CD) is an inflammatory bowel disease (IBD) characterized by chronic inflammation of the gastrointestinal tract. While any part of the gastrointestinal tract can be affected, inflammation is most commonly found at the end of the small intestine (ileum), and the start of the large intestine (colon).

GlobalData epidemiologists utilized national databases and robust peer-reviewed journal articles to build the CD forecast in the 7MM. CD is defined as a diagnosis of CD determined by medical record review, or a diagnosis of CD consistent with the International Classification of Diseases 9th edition (ICD-9) code 555.0 or 10th edition (ICD-10) code K50. Whenever available, country-specific sources were utilized. Appropriate proxies were used when data were not available. GlobalData epidemiologists also utilized primary market research (PMR) in the form of a high-prescribing physician survey to fill in gaps in the available literature.

GlobalData epidemiologists forecast that the diagnosed incident cases of CD in the 7MM will increase from 70,985 in 2016 to 74,712 in 2026 at an Annual Growth Rate (AGR) of 0.53%. The US will have the highest number of diagnosed incident cases of CD in both 2016 and 2026 at 44,886 and 47,477, respectively.

GlobalData epidemiologists forecast that the diagnosed prevalent cases of CD in the 7MM will increase from 1,621,866 in 2016 to 1,961,224 in 2026 at an AGR of 2.09%. The US will have the highest number of diagnosed prevalent cases of CD in both 2016 and 2026; however, France will have the highest AGR at 4.04%.

Scope

The Crohn’s Disease (CD) EpiCast Report and EpiCast Model provide an overview of the risk factors and global trends for CD in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed incident and diagnosed prevalent cases of CD in these markets. The diagnosed prevalent cases of CD are further segmented by sex and age in these markets. The diagnosed prevalent cases are further segmented by severity (mild to moderate, moderate to severe, and severe to fulminant) and by comorbid autoimmune diseases (psoriasis, ankylosing spondylitis, and pyoderma gangrenosum). Furthermore, an alternate forecast of diagnosed incident and diagnosed prevalent cases of CD is provided for markets where there was insufficient data to trend in the main forecast, to estimate the patient size if trending was applied.

The CD epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.

The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

The EpiCast Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to buy

The CD EpiCast series will allow you to:

Develop business strategies by understanding the trends shaping and driving the global CD market.

Quantify patient populations in the global CD market to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for CD therapeutics in each of the markets covered.

Understand magnitude of CD population by disease severity and comorbid autoimmune diseases.

Table of Contents

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Crohn’s Disease: Executive Summary

2.1 ...

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Crohn’s Disease: Executive Summary

2.1 Related Reports

2.2 Upcoming Reports

3 Epidemiology

3.1 Disease Background

3.2 Risk Factors and Comorbidities

3.3 Global and Historical Trends

3.3.1 US

3.3.2 5EU

3.3.3 Japan

3.4 Forecast Methodology

3.4.1 Sources

3.4.2 Forecast Assumptions and Methods

3.5 Epidemiological Forecast for Crohn’s Disease (2016–2026)

3.5.1 Diagnosed Incident Cases of Crohn’s Disease

3.5.2 Diagnosed Prevalent Cases of Crohn’s Disease

3.5.3 Age-Specific Diagnosed Prevalent Cases of Crohn’s Disease

3.5.4 Sex-Specific Diagnosed Prevalent Cases of Crohn’s Disease

3.5.5 Diagnosed Prevalent Cases of Crohn’s Disease by Severity

3.5.6 Diagnosed Prevalent Cases of Crohn’s Disease with Comorbid Autoimmune Diseases

3.6 Alternate Epidemiological Forecast for Crohn’s Disease (2016–2026)

3.6.1 Diagnosed Incident Cases of Crohn’s Disease

3.6.2 Diagnosed Prevalent Cases of Crohn’s Disease

3.7 Discussion

3.7.1 Epidemiological Forecast Insight

3.7.2 Limitations of Analysis

3.7.3 Strengths of Analysis

4 Appendix

4.1 Bibliography

4.2 Primary Research – KOLs Interviewed for this Report

4.3 Primary Research – Prescriber Survey

4.4 About the Authors

4.4.1 Epidemiologist

4.4.2 Reviewers

4.4.3 Global Director of Therapy Analysis and Epidemiology

4.4.4 Global Head and EVP of Healthcare Operations and Strategy

4.5 About GlobalData

4.6 Contact Us

4.7 Disclaimer

List of tables

Table 1: Risk Factors and Comorbidities for Crohn’s Disease

Table 2: 7MM, Diagnosed Incident Cases of CD, All Ages, Both Sexes, Select Years 2016 ...

Table 1: Risk Factors and Comorbidities for Crohn’s Disease

Table 2: 7MM, Diagnosed Incident Cases of CD, All Ages, Both Sexes, Select Years 2016–2026

Table 3: 7MM, Diagnosed Prevalent Cases of CD, Men and Women, All Ages, Select Years 2016–2026

Table 4: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of figures

Figure 1: 7MM, Diagnosed Incident Cases of CD, Both Sexes, All Ages, 2016 and 2026

Figure 2: 7MM, Diagnosed Prevalent Cases of CD, Both Sexes ...

Figure 1: 7MM, Diagnosed Incident Cases of CD, Both Sexes, All Ages, 2016 and 2026

Figure 2: 7MM, Diagnosed Prevalent Cases of CD, Both Sexes, All Ages, 2016 and 2026

Figure 3: 7MM, Age-Adjusted Diagnosed Prevalence of CD (%), Men, All Ages, 2006 to 2026

Figure 4: 7MM, Age-Adjusted Diagnosed Prevalence (%) of CD, Women, All Ages, 2006–2026

Figure 5: Sources Used and Not Used, Diagnosed Incident Cases of CD

Figure 6: Sources Used and Not Used, Diagnosed Prevalent Cases of CD

Figure 7: Sources Used, Diagnosed Prevalent Cases of CD with Comorbid Autoimmune Diseases

Figure 8: 7MM, Age-Specific Diagnosed Prevalent Cases of CD, Both Sexes, 2016

Figure 9: 7MM, Sex-Specific Diagnosed Prevalent Cases of CD, All Ages, 2016

Figure 10: 7MM, Diagnosed Prevalent Cases of CD by Severity, Both Sexes, All Ages, 2016

Figure 11: 7MM, Diagnosed Prevalent Cases of CD with Psoriasis, Ankylosing Spondylitis, and Pyoderma Gangrenosum, Both Sexes, All Ages, 2016

Figure 12: US and 5EU, Alternate Diagnosed Incident Cases of CD, Both Sexes, All Ages, 2016

Figure 13: Germany, Spain, Italy, and the UK, Alternate Diagnosed Prevalent Cases of CD, Both Sexes, All Ages, 2016

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Saved reports